Home › Prostate Cancer › Tennessee › Nashville
Prostate Cancer clinical trials in Nashville, TN
42 studies for Prostate Cancer are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
RecruitingPhase 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RecruitingPhase 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- and 7 more
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
RecruitingPhase 3
- Research Site, Nashville
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
RecruitingPhase 1/2
- GSK Investigational Site, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
RecruitingPhase 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RecruitingPhase 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RecruitingPhase 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- SCRI Oncology Partners, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RecruitingPhase 2
- Tennessee Oncology Nashville, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
RecruitingPhase 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
RecruitingPhase 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RecruitingPhase 2
- Henry-Joyce Cancer Clinic, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
RecruitingPhase 1/2
- Tennessee Oncology PLLC, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Investigative Site #102, Nashville
PSMA PET Combined With MRI for the Detection of PCa
RecruitingPhase 3Healthy volunteers welcome
- Urology Associates of Nashville, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RecruitingPhase 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- Chicago, IL45 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Seattle, WA42 studies
- Washington, DC38 studies
- Dallas, TX36 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer80 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
- Multiple Myeloma32 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.